E.S. Kim

Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

George D. Demetri, Luis Paz‐Ares, Anna F. Farago et al. · Annals of Oncology · 2018 · 63 citations · Full text

Surgical Oncology, Medicine, Cancer Management +6

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)

E.S. Kim, Vamsidhar Velcheti, Tarek Mekhail et al. · Annals of Oncology · 2018 · 62 citations · Full text

Medicine, Immunology, Pathology +7

Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001

George D. Demetri, Luis Paz‐Ares, Anna F. Farago et al. · Annals of Oncology · 2018 · 35 citations

Surgical Oncology, Medicine, Cancer Management +7

Blood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC

Tony Mok, Shirish M. Gadgeel, E.S. Kim et al. · Annals of Oncology · 2017 · 16 citations · Full text

Tumor Mutational Burden, Somatic Mutations, Medicine +10

Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low

Mohamed E. Salem, Alberto Puccini, Axel Grothey et al. · Annals of Oncology · 2018 · 11 citations · Full text